ZYBERNO
Stock Report
Updated Aug 31, 2026

Zentalis Pharmaceuticals, Inc. (ZNTL)

Healthcare • NASDAQ

$3.80

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
16.0/100
POOR BUSINESS
Zentalis Pharmaceuticals, Inc. (ZNTL) scores 16/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-53.6%)
Debt-to-Equity (Solvency Risk):GOOD (0.42x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-57.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Zentalis Pharmaceuticals, Inc. (ZNTL) stock report — Zyberno Score 16/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ZNTL generated -$125.60M in Owner Earnings. Capital was deployed as follows: $9.98M returned via share buybacks, $34.00K invested in capital expenditures. Reinvestment rate: 0.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.80
Market Cap:$267.00M

Valuation Multiples (2)

P/B Ratio:1.46x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$273.72M

Price Action & Momentum (3)

Momentum Percentile:99 / 100
% of 52-Week High:54.7%
B. Profitability Assessment

Return Metrics (5)

ROA:-40.7%
Reinvestment Rate:0.7%
Fundamental Growth Rate (g):-0.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$37.66
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:9.6%
Latest Earnings Filed:2026-05-12
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.19x
Quick Ratio:6.19x
Cash Ratio:0.91x

Leverage Analysis (3)

Debt To Equity Ttm:0.42x
Debt-to-Equity Ratio:0.42x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:182,860,000.00
Cash And Cash Equivalents:31,930,000.00
Long Term Debt:$34.65M
Net Debt:$6.72M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$145.04M

Bottom Line Performance (3)

-$124.13M
Income Before Tax:-$123.57M
Ebitda Ttm:-144,412,000.00

Operating Expenses (5)

Operating Expenses:145,040,000.00
R And D Expense:108,764,000.00
Sga Expense:36,276,000.00
Income Tax Expense:$562.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$253.07M
Current Assets:$218.10M
Ppe Net:2,653,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:70,386,000.00
Current Liabilities:35,236,000.00
Long Term Debt:$34.65M
Short Term Debt:$4.00M

Equity & Capital (3)

Equity:$182.68M
Retained Earnings:-$1.23B
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:27,858,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,197,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$125.57M-$125.60M

Investment Activities (2)

Investing Cash Flow:$30.01M
Capital Expenditures Ttm:34,000.00

Financing Activities (3)

Financing Cash Flow:-$1.12M
Dividends Paid Ttm:0.00
Stock Repurchase:9,976,000.00

Capital Transactions (3)

Common Stock Issuance:5,390,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:628,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.74
-$1.74
Earnings Per Share Ttm:-$1.77

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.78

Book Value & Capital (2)

Book Value Per Share:$2.60
Cash Per Share:0.45

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$125.60M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.7%
Fundamental Growth Rate (g):-0.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-16.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:ZNTL
Company Name:Zentalis Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:70.26M
Shares Outstanding Basic:70.26M
Shares Outstanding Diluted:70.26M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 04:19:33 UTC
Data Timestamp:2026-08-02T23:36:57.950542
Scroll to Top